Eli Lilly Stock Drops 7.48% Following Revenue Forecast Cut for Zepbound and Mounjaro

Eli Lilly's stock fell 7.48% after the company lowered its fourth-quarter revenue forecast for its weight-loss drug, Zepbound, and diabetes treatment, Mounjaro. The revision was due to an expected quick expansion in the U.S. incretin market and lower-than-expected channel inventory. Despite this, Eli Lilly maintains a positive long-term outlook with plans for strong future growth.